Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 8/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454455 | 0.86 | PRKDC (0.44) | PRKDCPKMTSHRPOLB | |
| SCHEMBL5448690 | 0.83 | PRKDC (0.45) | PRKDCKDM4E | |
| SCHEMBL14447676 | 0.81 | PRKDC (0.37) | PRKDCNPC1RAB9A | |
| SCHEMBL5451016 | 0.81 | PRKDC (0.41) | PRKDCPOLBKCNH2MCHR1ATM | |
| SCHEMBL5801743 | 0.81 | PRKDC (0.42) | PRKDCATMKDM4E | |
| SCHEMBL5440528 | 0.80 | PRKDC (0.42) | PRKDC | |
| SCHEMBL14468581 | 0.73 | PRKDC (0.38) | PRKDCNPC1RAB9AP2RY12 | |
| SCHEMBL5453418 | 0.73 | PRKDC (0.52) | PRKDCPKMPOLB | |
| SCHEMBL5454450 | 0.68 | PRKDC (0.48) | PRKDCPOLB | |
| SCHEMBL14802147 | 0.68 | PRKDC (0.40) | PRKDCKDM4EP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1660473-A2 | XANTHONES, THIOXANTHONES AND ACRIDINONES AS DNA-PK INHIBITORS | Luitpold Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2004085418-A2 | XANTHONES, THIOXANTHONES AND ACRIDINONES AS DNA-PK INHIBITORS | LUITPOLD PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | DCK, DTYMK, XPA | PRKDC 12/4885PKM 225/4885TSHR 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.